Publicacións en colaboración con investigadores/as de University of Manchester (73)

2023

  1. Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 53-60

  2. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709

  3. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician reported registry' by Arnaud and Devilliers

    Annals of the Rheumatic Diseases

2022

  1. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

    ACR Open Rheumatology, Vol. 4, Núm. 11, pp. 948-953

  2. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  3. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  4. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    RMD Open, Vol. 8, Núm. 2

  5. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: Results from the COVID-19 Global Rheumatology Alliance provider registry

    RMD Open, Vol. 8, Núm. 1

  6. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases

    Annals of the rheumatic diseases

  7. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry

    RMD Open, Vol. 8, Núm. 2

  8. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

    Annals of the rheumatic diseases, Vol. 81, Núm. 5, pp. 695-709

2021

  1. Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

    JAMA Network Open

  2. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1137-1146

  3. EULAR COVID-19 registry: Lessons learnt and future considerations

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 9, pp. 1110-1115

  4. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

    The Lancet Rheumatology, Vol. 3, Núm. 12, pp. e855-e864

2020

  1. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 7, pp. 859-866

  2. Line blot immunoassays in idiopathic inflammatory myopathies: Retrospective review of diagnostic accuracy and factors predicting true positive results

    BMC Rheumatology, Vol. 4, Núm. 1

  3. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries

    The Lancet Rheumatology

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  2. Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria

    Rheumatology (United Kingdom)